Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program

Malcolm A. Smith; Christopher L. Morton; E. Anders Kolb; Richard Gorlick; Stephen T. Keir; Hernan Carol; Richard Lock; Min H. Kang; C. Patrick Reynolds; John M. Maris; Amy E. Watkins; Peter J. Houghton

doi:10.1002/pbc.22188

Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program

Malcolm A. Smith, Christopher L. Morton, E. Anders Kolb, Richard Gorlick, Stephen T. Keir, Hernan Carol, Richard Lock, Min H. Kang, C. Patrick Reynolds, John M. Maris, Amy E. Watkins, Peter J. Houghton

Pediatrics

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that exclusively targets and activates tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). It was tested in vitro at concentrations from 0.01 to 100 μg/ml and in vivo at a dose of 10 mg/kg administered intraperitoneally using a twice-weekly schedule. Mapatumumab demonstrated limited activity against the 23 cell lines of the PPTP in vitro panel with no lines achieving 50% growth inhibition. Mapatumumab induced significant differences in event-free survival distribution compared to controls in 9 of 37 evaluable solid tumor xenografts tested, but in none of the 8 ALL xenografts.

Original language	English (US)
Pages (from-to)	307-310
Number of pages	4
Journal	Pediatric Blood and Cancer
Volume	54
Issue number	2
DOIs	https://doi.org/10.1002/pbc.22188
State	Published - Feb 2010

Keywords

Developmental therapeutics
Mapatumumab
Preclinical testing

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.22188

Cite this

@article{dd88188a660942b89d3fdb988aafc958,

title = "Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program",

abstract = "Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that exclusively targets and activates tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). It was tested in vitro at concentrations from 0.01 to 100 μg/ml and in vivo at a dose of 10 mg/kg administered intraperitoneally using a twice-weekly schedule. Mapatumumab demonstrated limited activity against the 23 cell lines of the PPTP in vitro panel with no lines achieving 50% growth inhibition. Mapatumumab induced significant differences in event-free survival distribution compared to controls in 9 of 37 evaluable solid tumor xenografts tested, but in none of the 8 ALL xenografts.",

keywords = "Developmental therapeutics, Mapatumumab, Preclinical testing",

author = "Smith, {Malcolm A.} and Morton, {Christopher L.} and Kolb, {E. Anders} and Richard Gorlick and Keir, {Stephen T.} and Hernan Carol and Richard Lock and Kang, {Min H.} and Reynolds, {C. Patrick} and Maris, {John M.} and Watkins, {Amy E.} and Houghton, {Peter J.}",

year = "2010",

month = feb,

doi = "10.1002/pbc.22188",

language = "English (US)",

volume = "54",

pages = "307--310",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "2",

}

TY - JOUR

T1 - Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program

AU - Smith, Malcolm A.

AU - Morton, Christopher L.

AU - Kolb, E. Anders

AU - Gorlick, Richard

AU - Keir, Stephen T.

AU - Carol, Hernan

AU - Lock, Richard

AU - Kang, Min H.

AU - Reynolds, C. Patrick

AU - Maris, John M.

AU - Watkins, Amy E.

AU - Houghton, Peter J.

PY - 2010/2

Y1 - 2010/2

N2 - Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that exclusively targets and activates tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). It was tested in vitro at concentrations from 0.01 to 100 μg/ml and in vivo at a dose of 10 mg/kg administered intraperitoneally using a twice-weekly schedule. Mapatumumab demonstrated limited activity against the 23 cell lines of the PPTP in vitro panel with no lines achieving 50% growth inhibition. Mapatumumab induced significant differences in event-free survival distribution compared to controls in 9 of 37 evaluable solid tumor xenografts tested, but in none of the 8 ALL xenografts.

AB - Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that exclusively targets and activates tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). It was tested in vitro at concentrations from 0.01 to 100 μg/ml and in vivo at a dose of 10 mg/kg administered intraperitoneally using a twice-weekly schedule. Mapatumumab demonstrated limited activity against the 23 cell lines of the PPTP in vitro panel with no lines achieving 50% growth inhibition. Mapatumumab induced significant differences in event-free survival distribution compared to controls in 9 of 37 evaluable solid tumor xenografts tested, but in none of the 8 ALL xenografts.

KW - Developmental therapeutics

KW - Mapatumumab

KW - Preclinical testing

UR - http://www.scopus.com/inward/record.url?scp=74849125377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74849125377&partnerID=8YFLogxK

U2 - 10.1002/pbc.22188

DO - 10.1002/pbc.22188

M3 - Article

C2 - 19856388

AN - SCOPUS:74849125377

SN - 1545-5009

VL - 54

SP - 307

EP - 310

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 2

ER -

Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this